News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accentia Biopharmaceuticals (ABPI) Announces Strategic Agreement with Baxter Healthcare Corporation (BAX)



11/29/2010 9:59:25 AM

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI) today announced a strategic agreement with Baxter Healthcare Corporation (NYSE: BAX) to provide Accentia with the exclusive, worldwide right to purchase Baxter’s cyclophosphamide, which is marketed under the brand name Cytoxan®, for the treatment of designated autoimmune diseases including multiple sclerosis. Cyclophosphamide is the active drug used in Revimmune™ therapy, Accentia’s proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES